For instance, if your genetic profile suggests higher sensitivity to gastroparesis-related symptoms, your provider might recommend a more gradual dose escalation or specific dietary interventions tailored to your microbiome composition
CrossRef Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study) Yongin Cho, Hyungjin Rhee, Young-eun Kim, Minyoung Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jin-Young Choi, Yong-ho Lee BMC Medicine.2022;[Epub] CrossRef Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee Hepatobiliary & Pancreatic Diseases International.2022
What the clinical trials showed at each dose Raw dose numbers mean nothing without understanding the outcomes they produce
Well, it certainly can